Released Nov 6, 2018, after the close
10-Q filed Nov 6, 2018, 37 days after period end · 0001232524-18-000192
Q3 2018 · 10-Q
Revenue$469.37M$469.37M +14.0% vs Q3 2017−6.2% vs Q2 2018
Net Income$149.32M$149.32M +135.0% vs Q3 2017+61.7% vs Q2 2018
EPS Diluted$2.41$2.41 +134.0% vs Q3 2017+60.7% vs Q2 2018
Gross Profit$438,623,000+16.4%
Operating Income$188,777,000+118.4%
Operating Cash Flowderived$221,475,000+17.2%
Free Cash Flowderived$217,535,000+20.5%
Margins · derived
Gross margin93.4%+2.0 pt vs Q3 2017
Operating margin40.2%+19.2 pt vs Q3 2017
Net margin31.8%+16.4 pt vs Q3 2017
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2018 | Q3 2017 | Q3 2016 | Q3 2015 |
|---|---|---|---|---|
| Revenue | $469.37M | $411.86M | $374.18M | $340.87M |
| Net Income | $149.32M | $63.53M | $89.83M | $87.96M |
| EPS Diluted | $2.41 | $1.03 | $1.45 | $1.39 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR